Timing of Testosterone Level Measurement for IM Testosterone Injections
For men receiving intramuscular testosterone enanthate or cypionate injections, draw testosterone levels midway between injections (at the trough, just before the next scheduled dose). 1
Rationale and Clinical Context
The Endocrine Society Clinical Practice Guidelines consistently recommend measuring serum testosterone at the midpoint between injections for injectable testosterone esters (enanthate or cypionate). 1, 2, 1 This timing provides the most clinically useful information for several reasons:
Why Midpoint/Trough Timing Matters
- Pharmacokinetic profile: IM testosterone cypionate and enanthate produce peak levels 2-5 days after injection, then decline to baseline by days 10-14 3, 4
- Wide fluctuations: Standard dosing (200 mg every 2 weeks) creates supraphysiological peaks early in the cycle and potentially subtherapeutic troughs late in the cycle 3, 5
- Clinical decision-making: Midpoint levels help determine if the patient maintains adequate testosterone throughout the dosing interval, not just at peak
Target Levels and Dose Adjustment
The goal is to achieve mid-normal range testosterone levels at the trough measurement. 1, 2
Adjust dosing if:
- Testosterone >700 ng/dL (24.5 nmol/L) at midpoint → reduce dose or frequency 1
- Testosterone <400 ng/dL (14.1 nmol/L) at midpoint → increase dose or frequency 1
- Testosterone <350 ng/dL (14.1 nmol/L) at midpoint per 2018 guidelines → increase dose or frequency 2
Timing of Initial Monitoring
Measure testosterone levels 3-6 months after initiating therapy, then annually once stable. 1, 2, 1 This allows time for steady-state levels to be achieved and provides adequate assessment of the dosing regimen.
Common Pitfalls to Avoid
Drawing levels at peak (days 2-5): This will show artificially elevated levels and may lead to inappropriate dose reduction when the patient actually has inadequate trough levels 3
Not documenting injection timing: Without knowing when the last injection was given, testosterone results are uninterpretable 6
Ignoring symptom cycling: If patients report early-cycle symptoms (acne, mood changes, fluid retention) or late-cycle hypogonadal symptoms (fatigue, low libido), consider more frequent dosing rather than just adjusting total dose 6, 5
Assuming all patients need the same interval: While every-2-week dosing is traditional, weekly or more frequent dosing may provide more stable levels and better symptom control for many patients 7, 6, 8
Alternative Consideration
Some clinicians measure levels just before the next injection (true trough) rather than midway between injections. 7 This approach ensures the patient maintains adequate testosterone even at the lowest point in the cycle. Both approaches are clinically reasonable, but the key is consistency in timing and documentation so results can be properly interpreted over time.